Correspondence 0001193125-23-299991 from Korro Bio, Inc. (KRRO) (CIK 0001703647) (KRRO)
Korro Bio, Inc. (KRRO) (CIK 0001703647)
Date: Dec. 20, 2023 · CIK: 0001703647 · Accession: 0001193125-23-299991
AI Filing Summary & Sentiment
File numbers found in text: 333-275353
Referenced dates: December 6, 2023
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Attention: Ms. Doris Stacey Gama Re: Korro Bio, Inc. Amendment No. 1 to Registration Statement S-3 on Form S-1 Filed December 1, 2023 File No. 333-275353
Dear Ms. Gama and Mr. McCann:
This letter is submitted on behalf of Korro Bio, Inc. (“Korro”) in response to the comment of the staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) with respect to Korro’s Amendment No. 1 to Registration Statement S-3 on Form S-1 (File No: 333-275353), filed on December 1, 2023 (the “Registration Statement”), as set forth in the Staff’s letter dated December 6, 2023 (the “Comment Letter”).
In connection with this letter responding to the Comment Letter, the Company is concurrently filing Amendment No. 2 to Registration Statement S-3 on Form S-1 (“Amendment No. 2”), which reflects certain revisions to the Registration Statement in response to the Comment Letter as well as certain other changes.
For reference purposes, the text of the Comment Letter has been reproduced herein with the response below the numbered comment.
Amendment No.1 to Form S-3 on Form S-1
General
1. We note the representation in Section 3.4 of the Agreement and Plan of Merger, filed on July 14, 2023 as exhibit 2.1 to Frequency Therapeutics, Inc.’s Form 8-K, that Korro’s stockholders were required to consent to the merger. We further note your Form S-1 seeks to register the resale of securities issued to Korro’s security holders in connection with the merger. Please revise to identify all former affiliates of Korro reselling pursuant to this Form S-1 as underwriters and fix a selling price for the duration of their offering. See Securities Act Rule 145(c).
RESPONSE: Korro respectfully acknowledges the Staff’s comment and while it respectfully disagrees with the Staff’s position regarding applicability of Rule 145(c), it has nevertheless revised the selling stockholder table to remove those selling stockholders who may have been deemed to be affiliates within the meaning of Rule 145(c) at the time of the vote on the merger. See pages 200-203.
***
U.S. Securities and Exchange Commission
December 20, 2023
Page
If you should have any questions or comments with respect to the foregoing, please contact me at (415) 733-6134 or via e-mail at msarrazin@goodwinlaw.com.
Very truly yours,
/s/ Marianne Sarrazin
Show Raw Text
CORRESP 1 filename1.htm Response Letter Goodwin Procter LLP Three Embarcadero Center, 28th Floor San Francisco, CA 94111 goodwinlaw.com +1 (415) 733-6000 December 20, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Attention: Ms. Doris Stacey Gama Mr. Joe McCann Re: Korro Bio, Inc. Amendment No. 1 to Registration Statement S-3 on Form S-1 Filed December 1, 2023 File No. 333-275353 Dear Ms. Gama and Mr. McCann: This letter is submitted on behalf of Korro Bio, Inc. (“Korro”) in response to the comment of the staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) with respect to Korro’s Amendment No. 1 to Registration Statement S-3 on Form S-1 (File No: 333-275353), filed on December 1, 2023 (the “Registration Statement”), as set forth in the Staff’s letter dated December 6, 2023 (the “Comment Letter”). In connection with this letter responding to the Comment Letter, the Company is concurrently filing Amendment No. 2 to Registration Statement S-3 on Form S-1 (“Amendment No. 2”), which reflects certain revisions to the Registration Statement in response to the Comment Letter as well as certain other changes. For reference purposes, the text of the Comment Letter has been reproduced herein with the response below the numbered comment. Amendment No.1 to Form S-3 on Form S-1 General 1. We note the representation in Section 3.4 of the Agreement and Plan of Merger, filed on July 14, 2023 as exhibit 2.1 to Frequency Therapeutics, Inc.’s Form 8-K, that Korro’s stockholders were required to consent to the merger. We further note your Form S-1 seeks to register the resale of securities issued to Korro’s security holders in connection with the merger. Please revise to identify all former affiliates of Korro reselling pursuant to this Form S-1 as underwriters and fix a selling price for the duration of their offering. See Securities Act Rule 145(c). RESPONSE: Korro respectfully acknowledges the Staff’s comment and while it respectfully disagrees with the Staff’s position regarding applicability of Rule 145(c), it has nevertheless revised the selling stockholder table to remove those selling stockholders who may have been deemed to be affiliates within the meaning of Rule 145(c) at the time of the vote on the merger. See pages 200-203. *** U.S. Securities and Exchange Commission December 20, 2023 Page 2 If you should have any questions or comments with respect to the foregoing, please contact me at (415) 733-6134 or via e-mail at msarrazin@goodwinlaw.com. Very truly yours, /s/ Marianne Sarrazin Marianne Sarrazin Cc: Ram Aiyar, Korro Bio, Inc. Vineet Agarwal, Korro Bio, Inc. Shelby Walker, Korro Bio, Inc. Kingsley L. Taft, Goodwin Procter LLP Daniel Hughes, Goodwin Procter LLP